FourKites and RCS Logistics Partner to Bring End-to-End Multimodal Visibility to Customers Worldwide
16.2.2023 11:00:00 EET | Business Wire | Press release
Leading supply chain visibility company FourKites and RCS Logistics, one of the world’s leading independent logistics service providers, today announced a partnership to provide RCS customers with a one-stop shop for end-to-end visibility into their shipments across ocean, air, drayage, intermodal and over-the-road (OTR). Leveraging FourKites’ industry-leading real-time supply chain data, RCS’s internal teams and customers are benefiting from automated, real-time visibility into the status and location of shipments in transit and at rest, all over the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230216005067/en/
FourKites and RCS Logistics Partner to Bring End-to-End Multimodal Visibility to Customers Worldwide (Photo: Business Wire)
“FourKites’ supply chain visibility platform is a game-changer for RCS Logistics,” says Brian Heaney, President at RCS Logistics. “By providing comprehensive end-to-end visibility data, the industry’s most accurate predictive ETAs and real-time status into shipments, our internal teams are much more efficient and able to focus on higher-value services, while our customers and partners receive a holistic view of their supply chain and shipments. It’s a modern, world-class experience that every stakeholder — large and small — can now enjoy.”
Since deploying the FourKites platform — including the company’s Dynamic Ocean ® solution — in Q3 2022 to track ocean, drayage and OTR shipments, RCS has achieved 7x growth in its domestic transport services, while its ocean freight business has grown 12x. “We are known in the industry as a leading air freight forwarder,” notes Brian Aldridge, SVP Sales, at RCS. “With FourKites, we’ve been able to elevate our ocean freight experience, and connect the dots with other modes, to truly differentiate ourselves in the market. Our customers and partners appreciate FourKites’ simple, modern interface, and the transparency it creates across their supply chain.”
With FourKites in place, track-and-trace teams, drayage providers and warehouse staff have been alleviated of time-consuming manual tracking processes. Moreover, RCS’s data analysts are leveraging FourKites’ advanced analytics — which provide insights into on-time performance, dwell and detention costs, tracking quality, lane and mode performance, and more — to drive continuous improvements in every aspect of the company’s operations.
“We are thrilled to partner with a leader like RCS Logistics, which shares our vision for automated, interconnected and collaborative digital global supply chains, end to end,” says Brad Klaus, Group Vice President, International Solutions, at FourKites. “Our work together illustrates how we integrate across the supply chain ecosystem to modernise operations and provide a superior customer experience in the process.”
Building on the success it has seen to date with ocean, drayage and OTR shipment visibility, the two companies are now working to bring greater visibility to RCS Logistics’ leading door-to-door international air freight forwarding solutions.
About RCS Logistics
RCS Logistics is one of the world’s leading logistics providers specializing in international air, ocean and land freight forwarding, supply chain management, 3PL, trucking transportation, distribution, customs brokerage, and other logistics solutions. To learn more, visit http://www.rcslogistics.com/.
About FourKites
Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230216005067/en/
Contact information
Scott Johnston
European PR Director FourKites
+31 62 147 8442
sscott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom